A medical device determining the daily amount of breast milk to improve neonatal nutrition andmothers’ psychophysics well-being.

Informazioni relative al progetto

Galastick

ID dell’accordo di sovvenzione: 728382

DOI

10.3030/728382

Progetto chiuso

Data della firma CE 10 Maggio 2016

Data di avvio 1 Giugno 2016

Data di completamento 30 Settembre 2016

Finanziato da

• SOCIETAL CHALLENGES - Europe In A Changing World - Inclusive, Innovative And Reflective Societies

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

GALASCREEN SRLS
Italy

Periodic Reporting for period 1 - Galastick (A medical device determining the daily amount of breast milk to improve neonatal nutritionandmothers’ psychophysics well-being.)

Periodo di rendicontazione: 2016-06-01 al 2016-09-30

Sintesi del contesto e degli obiettivi generali del progetto

"Less than 40% of infants are exclusively breastfed globally and the goal for WHO by 2025 is it to increase until 50%. If every child were breastfed within an hour of birth, and then continually breastfed until 2 years, about 800,000 child lives would be saved every year. The questions are: Do I have enough milk? Is my milk effective to defend my baby from illnesses?
GalaStick is a disposable medical device able to determining the lactation onset and the progressively increasing daily amount of breastmilk. The stick uses a lateral flow immunochromatographic assay that works simply detecting the presence (or absence) of a target analyte in the human milk sample. ""Biological diversity among people, reveals that not all mothers are the same. For some of them (not a few) it occurs that they are not able to successfully breastfeed their babies. Breastfeeding without ""feeding"" can cause frequent crying and colic in the newborn and nervousness in mothers, lack of confidence in their abilities and depression. A mother starts to feel inadequate, undermining her psychological wellness. On the other hand, several mothers have breastmilk in excess and could donate it to preterm infants in midwiferies, thus promoting the babies' health and reduce hospitals' costs.
"

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The main objective of the Phase 1 project was to elaboration of a comprehensive and soundness business plan and deepen the study on the requirements and standards for medical devices and define a minimum viable product for the GalaStick. Market survey was show several potential competitor and competitive solution. The pricing for each segment and commercialization strategy was defined.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

GalaStick offers this unique value to measure milk amount and milk immune profile identify a key element (the p-LAP) and its supports all mums in several lactation phases: from beginning of the breastmilk to weaning by reaching the condition of long breastfeed. The market analysis of this feasibility study highlighted that breastfeeding supplies in Europe is forecast to grow at a Compounded Average Growth Rate (CAGR) of 4.44% during the next 4 years (2016-2020). Our analysis shows that no similar medical devices are on the market by according to its scientific basis, technical functions, usability and accuracy, which represent key properties for lactating mothers. Since the biomarker discovery made by GalaScreen represents the first time that this biomarker has been isolated so it has never been reported anywhere, neither in the scientific literature nor in the patent literature. Galastick verifies in real time milk properties for a long and conscious babies nutrition.

logo.jpg